Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study

Mark Gurnell; Christian  Domingo; Klaus F Rabe; Andrew Menzies-Gow; David Price; Guy  Brusselle; Michael E Wechsler; Changming  Xia; Michel  Djandji; Rebecca Gall; Juby A.  JacobNara; Paul J.  Rowe; Yamo  Deniz; Shahid  Siddiqui

Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study

Mark Gurnell, Christian Domingo, Klaus F Rabe, Andrew Menzies-Gow, David Price, Guy Brusselle, Michael E Wechsler, Changming Xia, Michel Djandji, Rebecca Gall, Juby A. JacobNara, Paul J. Rowe, Yamo Deniz, Shahid Siddiqui

Research output: Contribution to conference › Abstract › peer-review

Original language	English
Publication status	Accepted/In press - 28 Jul 2022
Event	17th Annual Deutscher Allergiekongress (DAK) 2022 - RheinMain Congress Center, Wiesbaden, Germany Duration: 8 Sept 2022 → 10 Sept 2022 Conference number: 17 https://allergiekongress.de/

Conference

Conference	17th Annual Deutscher Allergiekongress (DAK) 2022
Abbreviated title	17th Annual Deutscher Allergiekongress (DAK) 2022
Country/Territory	Germany
City	Wiesbaden
Period	8/09/22 → 10/09/22
Internet address	https://allergiekongress.de/

Bibliographical note

Acknowledgments and funding sources
Data first presented at the 118th International Conference of the American Thoracic Society (ATS 2022); San Francisco, CA, USA; May 13–18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good
Publication Practice guideline. Alternate presenters: Anne Atenhan and Mayank Thakur.

Cite this

Gurnell, M., Domingo, C., Rabe, K. F., Menzies-Gow, A., Price, D., Brusselle, G., Wechsler, M. E., Xia, C., Djandji, M., Gall, R., JacobNara, J. A., Rowe, P. J., Deniz, Y., & Siddiqui, S. (Accepted/In press). Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study. Abstract from 17th Annual Deutscher Allergiekongress (DAK) 2022, Wiesbaden, Germany.

Gurnell, M, Domingo, C, Rabe, KF, Menzies-Gow, A, Price, D, Brusselle, G, Wechsler, ME, Xia, C, Djandji, M, Gall, R, JacobNara, JA, Rowe, PJ, Deniz, Y & Siddiqui, S 2022, 'Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study', 17th Annual Deutscher Allergiekongress (DAK) 2022, Wiesbaden, Germany, 8/09/22 - 10/09/22.

@conference{308240f80e8944d3bae86c50a6f52ba9,

title = "Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab: LIBERTY ASTHMA TRAVERSE Study",

author = "Mark Gurnell and Christian Domingo and Rabe, {Klaus F} and Andrew Menzies-Gow and David Price and Guy Brusselle and Wechsler, {Michael E} and Changming Xia and Michel Djandji and Rebecca Gall and JacobNara, {Juby A.} and Rowe, {Paul J.} and Yamo Deniz and Shahid Siddiqui",

note = "Acknowledgments and funding sources Data first presented at the 118th International Conference of the American Thoracic Society (ATS 2022); San Francisco, CA, USA; May 13–18, 2022. Research sponsored by Sanofi and Regeneron Pharmaceuticals, Inc. ClinicalTrials.gov Identifiers: NCT02528214 (VENTURE)/NCT02134028 (TRAVERSE). Medical writing/editorial assistance was provided by Anthony Aggidis, PhD, of Excerpta Medica, and was funded by Sanofi and Regeneron Pharmaceuticals, Inc., according to the Good Publication Practice guideline. Alternate presenters: Anne Atenhan and Mayank Thakur. ; 17th Annual Deutscher Allergiekongress (DAK) 2022, 17th Annual Deutscher Allergiekongress (DAK) 2022 ; Conference date: 08-09-2022 Through 10-09-2022",

year = "2022",

month = jul,

day = "28",

language = "English",

url = "https://allergiekongress.de/",

}

TY - CONF

T1 - Persistent Reductions in OCS Use in Patients With Severe, OCS-Dependent Asthma Treated With Dupilumab

T2 - 17th Annual Deutscher Allergiekongress (DAK) 2022

AU - Gurnell, Mark

AU - Domingo, Christian

AU - Rabe, Klaus F

AU - Menzies-Gow, Andrew

AU - Price, David

AU - Brusselle, Guy

AU - Wechsler, Michael E

AU - Xia, Changming

AU - Djandji, Michel

AU - Gall, Rebecca

AU - JacobNara, Juby A.

AU - Rowe, Paul J.

AU - Deniz, Yamo

AU - Siddiqui, Shahid

N1 - Conference code: 17

PY - 2022/7/28

Y1 - 2022/7/28

M3 - Abstract

Y2 - 8 September 2022 through 10 September 2022

ER -